Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200194 | 1.00 | LMNA (0.52) | LMNAMAPK1ALOX5LCKFYN | |
| SCHEMBL11520740 | 0.81 | ALOX5 (0.47) | LMNAMAPK1ALOX5LCKFYN | |
| SCHEMBL10759383 | 0.81 | ALOX5 (0.56) | ALOX5LCKFYNDAOCES2 | |
| SCHEMBL14416057 | 0.81 | ALOX5 (0.51) | LMNAMAPK1ALOX5LCKFYN | |
| SCHEMBL18734632 | 0.80 | CYP2D6 (0.50) | LMNAMAPK1ALOX5LCKFYN | |
| SCHEMBL162736 | 0.80 | SRC (0.50) | LMNAMAPK1ALOX5LCKFYN | |
| SCHEMBL14671259 | 0.79 | ALOX5 (0.42) | LMNAMAPK1ALOX5LCKFYN | |
| SCHEMBL18169428 | 0.79 | ALOX5 (0.42) | LMNAMAPK1ALOX5LCKFYN | |
| SCHEMBL6775406 | 0.79 | CES2 (0.63) | LMNAMAPK1ALOX5LCKFYN | |
| Hydrochloric Acid SCHEMBL11244144 | 0.78 | SRC (0.48) | ALOX5LCKFYNDAOCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2657227-B1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-2657227-B1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-04-27 | — | — | EP | disclosed |
| CN-103270024-B | Novel substituted isoquinoline derivative | WESTERN THERAPEUTICS INST INC | 2015-07-08 | — | — | CN | disclosed |
| US-8883792-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883792-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8883792-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2657227-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-2657227-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2013-10-17 | — | — | US | disclosed |
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2013-10-17 | — | — | US | disclosed |
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2013-10-17 | — | — | US | disclosed |
| CN-103270024-A | Novel substituted isoquinoline derivative | WESTERN THERAPEUTICS INST INC | 2013-08-28 | — | — | CN | disclosed |
| EP-0424021-B1 | Antimuscarinic bronchodilators | PFIZER LTD (GB) | 1994-03-02 | — | — | EP | disclosed |
| US-5171744-A | Antimuscarinic bronchodilators | PFIZER INC. (US) | 1992-12-15 | — | — | US | disclosed |
| EP-0424021-A1 | Antimuscarinic bronchodilators | Pfizer Limited (GB) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274269-A1 | NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT2A1, SULT1A1, SFPQ | LMNA 4114/4885MAPK1 2444/4885ALOX5 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.